Literature DB >> 15167623

Topiramate serum concentration-to-dose ratio: influence of age and concomitant antiepileptic drugs and monitoring implications.

Javier Adín1, M Cruz Gómez, Yolanda Blanco, José L Herranz, Juan A Armijo.   

Abstract

The influence of age and concomitant antiepileptic drugs (AEDs) on the trough steady-state serum concentration of topiramate, normalized to 1 mg/kg body weight or concentration-to-dose ratio (TPM-CDR), was assessed using multivariate methods in samples from 94 epileptic patients (38 under 11 years and 56 over 11 years of age), most of whom were outpatients receiving either just TPM (n = 20) or TPM in combination with other AEDs (n = 74). Analysis of the covariance showed that the age of the patients was influential (P < 0.001) and also showed a difference in TPM-CDR between the non-inducers group (TPM or TPM + lamotrigine or valproate) and the inducers group (TPM + carbamazepine, phenobarbital, or phenytoin) (P < 0.001). The TPM-CDR was 0.4 +/- 0.1 in patients under 11 years with inducers (n = 7), 0.8 +/- 0.3 in patients over 11 years with inducers (n = 32), 1.1 +/- 0.4 in patients under 11 years with noninducers (n = 30), and 1.8 +/- 0.6 in patients over 11 years with noninducers (n = 21). A two-way analysis of the variance showed differences between patients under 11 years and those over 11 years (P < 0.001), and between the noninducers and inducers groups (P < 0.001). TPM-CDR was nearly 50% lower in patients under 11 years than in patients over 11 years, and in patients with TPM + inducers than in patients with TPM or TPM + noninducers, in both children and adults. To achieve the same serum concentration of TPM, children will need double the daily dose per kilogram of TPM required by adults, and both children and adults taking enzyme-inducing AEDs will require double the dose needed by those who do not take them.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15167623     DOI: 10.1097/00007691-200406000-00005

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  9 in total

Review 1.  Management of focal-onset seizures: an update on drug treatment.

Authors:  Svein I Johannessen; Elinor Ben-Menachem
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 2.  Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed?

Authors:  Svein I Johannessen; Torbjörn Tomson
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

3.  Topiramate pharmacokinetics in children and adults with epilepsy: a case-matched comparison based on therapeutic drug monitoring data.

Authors:  Dina Battino; Danilo Croci; Alessandro Rossini; Sara Messina; Daniela Mamoli; Emilio Perucca
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 4.  Pharmacokinetics and therapeutic drug monitoring of newer antiepileptic drugs during pregnancy and the puerperium.

Authors:  Torbjörn Tomson; Dina Battino
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 5.  Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age.

Authors:  Emilio Perucca
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 6.  Molecular pharmacodynamics, clinical therapeutics, and pharmacokinetics of topiramate.

Authors:  Richard P Shank; Bruce E Maryanoff
Journal:  CNS Neurosci Ther       Date:  2008       Impact factor: 5.243

Review 7.  Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age: an update.

Authors:  Domenico Italiano; Emilio Perucca
Journal:  Clin Pharmacokinet       Date:  2013-08       Impact factor: 6.447

Review 8.  Drug interactions with the newer antiepileptic drugs (AEDs)--part 1: pharmacokinetic and pharmacodynamic interactions between AEDs.

Authors:  Philip N Patsalos
Journal:  Clin Pharmacokinet       Date:  2013-11       Impact factor: 6.447

9.  Antiepileptic drug interactions - principles and clinical implications.

Authors:  Svein I Johannessen; Cecilie Johannessen Landmark
Journal:  Curr Neuropharmacol       Date:  2010-09       Impact factor: 7.363

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.